Protagenic Therapeutics’ practical-minded scientists and
management are focused on realizing the potential of one
of nature’s most highly-conserved neuropeptides.

Garo H. Armen, Ph.D.

Executive Chairman

Brian Corvese

Brian J. Corvese


Robert B. Stein, Ph.D., MD


Joshua Silverman


Khalil Barrage


Board of Directors

An effective team pursuing an exciting goal


In our mission to provide innovative, safe and effective treatments for anxiety and depression by using neuropeptide hormones to restore normal emotionality, we have the advantage of one of nature’s most highly-conserved neuropeptides.


A compound believed to be found in the brains of every animal ever studied (from fruit flies to humans), but that has never been made into a pharmaceutical agent before, is our inspiration. It is protected by our unique intellectual property portfolio, and pursued by our multi-functional team. Together, we have collectively taken multiple previous drug candidates from discovery to clinic. 

PTI is committed to advancing its biological expertise to help build a strong presence with novel, first-in-class approaches in the treatment of a variety of psychological and psychiatric diseases. We believe that understanding the biology of disease, as well as the mechanism of action of a potential intervention, will help facilitate more efficient and speedy clinical development while improving the probabilities of success in clinical trials. We expect our IND-enabling studies to be completed in the next 18 months, followed by IND submission to the FDA in the first half of 2018. If this IND is accepted by the FDA, we anticipate being able to commence Phase I clinical trials in 2018.

[Team image courtesy of the University of Toronto]

A highly-conserved endogenous stimulator